Want to see PETS full AI Analyst Report?
PETS Stock Chart & Stats
$1.77
-$0.25(-5.00%)
At close: 4:00 PM EST
$1.77
-$0.25(-5.00%)
Day’s Range― - ―
52-Week Range$1.57 - $4.10
Previous CloseN/A
Volume75.70K
Average Volume (3M)1.27M
Market Cap
$42.74M
Enterprise Value$17.58M
Total Cash (Recent Filing)$21.41M
Total Debt (Recent Filing)$535.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 27, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding21,371,880
10 Day Avg. Volume3,395,869
30 Day Avg. Volume1,269,064
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.65
Price to Sales (P/S)0.27
P/FCF Ratio-1.45
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.43
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)$180.32M
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe business is well-capitalized to make it through the turnaround, with $50M of cash and no debt.
Management StrategyThe new strategy is focused on consolidating brands, improving the supply chain, focusing on customer retention, driving site traffic, improving the marketing approach, and upgrading the technology platforms.
Bears Say
Customer RetentionThe company is likely losing customers to competitors with the absence of promotions.
Financial PerformanceThe business has not shown growth on an organic basis in over 12 quarters, which is largely driven by competitive pressures.
Revenue DeclineQ2 revenue declined 16% to $59.6M, which was below the $66.0M estimate, indicating customers reduced spending or sought promotions from competitors.
Petmed Express News
PETS FAQ
What was Petmed Express’s price range in the past 12 months?
Petmed Express lowest stock price was $1.57 and its highest was $4.10 in the past 12 months.
What is Petmed Express’s market cap?
Petmed Express’s market cap is $42.74M.
When is Petmed Express’s upcoming earnings report date?
Petmed Express’s upcoming earnings report date is Jul 27, 2026 which is in 18 days.
How were Petmed Express’s earnings last quarter?
Petmed Express released its earnings results on Jun 02, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.01.
Is Petmed Express overvalued?
According to Wall Street analysts Petmed Express’s price is currently Overvalued.
Does Petmed Express pay dividends?
Petmed Express pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Petmed Express dividends here
What is Petmed Express’s EPS estimate?
Petmed Express’s EPS estimate is 0.12.
How many shares outstanding does Petmed Express have?
Petmed Express has 21,371,880 shares outstanding.
What happened to Petmed Express’s price movement after its last earnings report?
Petmed Express reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -16.432%.
Which hedge fund is a major shareholder of Petmed Express?
Currently, no hedge funds are holding shares in PETS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Petmed Express Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 273.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $43.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.36%
12-Months-Change
Fundamentals
Return on Equity
-146.59%
Trailing 12-Months
Asset Growth
-45.40%
Trailing 12-Months
Company Description
Petmed Express
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.
PETS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call highlights meaningful operational, governance and technology progress — including remediation of material weaknesses, cost-savings actions (~$6.1M annualized), Q4 sequential sales improvement, expanded tech infrastructure, and a clean balance sheet with $21.4M cash and no debt. However, these positives were offset by significant financial deterioration: a 21.1% decline in FY sales, a substantial FY net loss of $57.3M driven largely by a $26.7M goodwill impairment and other nonrecurring charges, and negative adjusted EBITDA of $15.4M. Management emphasized stabilization and early signs of improvement in the second half, but the magnitude of the year-over-year deterioration in top-line and profitability represents a material near-term challenge.View all PETS earnings summariesTechnical Analysis
Ownership Overview
26.30% Insiders
12.05% Mutual Funds
4.94% Other Institutional Investors
51.41% Public Companies and
Individual Investors